Distorted octahedral environments in tricarbonylrhenium(I) complexes of 5-[2-(2,4,6-trimethylphenyl)diazen-1-yl]quinolin-8-olate and 5,7-bis[2-(2-methylphenyl)diazen-1-yl]quinolin-8-olate

Tricarbonyl rhenium(i) complexes with 8-hydroxyquinolines: structural, chemical, antibacterial, and anticancer characteristics

Twelve tricarbonyl rhenium(i) complexes in the '2 + 1' system with the anionic bidentate N,O-donor ligand (deprotonated 8-hydroxyquinoline (HQ) or its 2-methyl (MeHQ) or 5-chloro (ClHQ) derivative) and neutral N-donor diazoles (imidazole (Him), 2-methylimidazole (MeHim), 3,5-dimethylpyrazole (Hdmpz), and 3-phenylpyrazole (HPhpz)) were synthesized: [Re(CO)3(LN,O)LN] (LN,O = Q-, MeQ-, ClQ-; LN = Him, MeHim, Hdmpz, HPhpz). Their crystal structures were determined by the scXRD method, compared with the DFT-calculated ones, and characterized by analytical (EA) and spectroscopic techniques (FT-IR, NMR, and UV-Vis) interpreted with DFT and TD-DFT calculations. Most of the Re(i) complexes did not show relevant antibacterial activity against Gram-negative and Gram-positive bacterial strains. Only [Re(CO)3(MeQ)Him] demonstrated significant action 4-fold better against Gram-negative Pseudomonas aeruginosa than the free MeHQ ligand. The cytotoxicity of the compounds was estimated using human acute promyelocytic leukemia (HL-60), ovarian (SKOV-3), prostate (PC-3), and breast (MCF-7) cancer, and breast non-cancerous (MCF-10A) cell lines. Only HQ and ClHQ ligands and [Re(CO)3(Q)Hdmpz] complex had good selectivity toward MCF-7 cell line. HL-60 cells were sensitive to all complexes (IC50 = 1.5-14 μM). Still, pure HQ and ClHQ ligands were slightly more active than the complexes.

Comparison of a dimeric and a monomeric indium-quinolinato complex: synthesis, structure and photoluminescence

Two indium(iii) complexes, mer-[In(Ox)₃]·2H₂O (1) and [In₂(Ox)₂Cl₂-μ-[κ²-O,O′-(Ox)₂]]·C₇H₈ (2) (Ox = 8-hydroxyquinolinate), were synthesized and characterised for comparison by NMR, X-ray diffraction and photoluminescence.

Crystal structure of 3,5,7-tris(morpholinomethyl)tropolone·0.67 hydrate, C22H33N3O5·0.67H2O

C22H33N3O5·0.67H2O, monoclinic, P21/c, a = 11.9915(6) Å, b = 18.9934(10) Å, c = 10.5332(5) Å, β = 112.155(2)°, V = 2221.91(19) Å3, Z = 4, R gt(F) = 0.0417, wR ref(F 2) = 0.1139, T = 100(2) K.

Crystal structure of fac-hexacarbonylbisμ2-(3-carboxy-3′-carboxylato-2,2′-bipyridine)-κ3N,N′:O-dirhenium(I) tetrahydrate, C30H22N4O18Re2

C30H22N4O18Re2, monoclinic, P21/c (no. 14), a = 10.167(7) Å, b = 17.57(1) Å, c = 19.95(1) Å, β = 98.75(1)°, V = 3522(9) Å3, Z = 4, Rgt(F) = 0.0275, wRref(F2) = 0.0633, T = 100(2) K.

Crystal structure of fac-tricarbonyl(2-(isopropylimino)methyl-5-methylphenolatido-κ2 N,O)(pyridine-κN)rhenium(I), C19H19N2O4Re

C19H19N2O4Re, Monoclinic, P21/c (no. 14), a = 8.2805(3) Å, b = 13.7325(5) Å, c = 16.3560(6) Å, β = 92.431(2)°, V = 1858.2(2) Å3, Z = 4, R gt (F) = 0.0347, wR ref (F 2 ) = 0.0930, T = 100 K.